key: cord-0831138-9y6x3j3n
authors: dos-Santos, Júlio Souza; Firmino-Cruz, Luan; Fonseca-Martins, Alessandra Marcia da; Oliveira-Maciel, Diogo; Perez, Gustavo Guadagini; Pereira, Victor A. R.; Dumard, Carlos H.; Guedes-da-Silva, Francisca H.; Santos, Ana C. Vicente; Leandro, Monique dos Santos; Machado Ferreira, Jesuino Rafael; Guimarães-Pinto, Kamila; Conde, Luciana; Rodrigues, Danielle A. S.; Vinicius de Mattos Silva, Marcus; Alvim, Renata G. F.; Lima, Tulio M.; Marsili, Federico F.; Abreu, Daniel P. B.; Ferreira, Orlando; Borges, Ronaldo da Silva Mohana; Tanuri, Amilcar; Souza, Thiago Moreno L.; Rossi-Bergamnn, Bartira; Vale, André M.; Silva, Jerson Lima; de Oliveira, Andrea Cheble; Filardy, Alessandra D’Almeida; Gomes, Andre M. O.; de Matos Guedes, Herbert Leonel
title: Immunogenicity of SARS-CoV-2 trimetric spike protein associated to Poly(I:C) plus Alum
date: 2021-10-11
journal: bioRxiv
DOI: 10.1101/2021.10.05.461434
sha: fcf8e679aee0aa01964b2f4c6c77457aaab7a130
doc_id: 831138
cord_uid: 9y6x3j3n

The SARS-CoV-2 pandemic has had a social and economic impact worldwide, and vaccination is an efficient strategy for diminishing those damages. New adjuvant formulations are required for the high vaccine demands, especially adjuvant formulations that induce a Th1 phenotype. Herein we assess a vaccination strategy using a combination of Alum and polyinosinic:polycytidylic acid (Poly(I:C)) adjuvants plus the SARS-CoV-2 spike protein in a prefusion trimeric conformation by an intradermal (ID) route. We found high levels of IgG anti-spike antibodies in the serum by enzyme linked immunosorbent assay (ELISA) and high neutralizing titers against SARS-CoV-2 in vitro by neutralization assay, after one or two boosts. By evaluating the production of IgG subtypes, as expected, we found that formulations containing Poly(I:C) induced IgG2a whereas Alum did not. The combination of these two adjuvants induced high levels of both IgG1 and IgG2a. In addition, cellular immune responses of CD4+ and CD8+ T cells producing interferon-gamma were equivalent, demonstrating that the Alum + Poly(I:C) combination supported a Th1 profile. Based on the high neutralizing titers, we evaluated B cells in the germinal centers, which are specific for receptor-binding domain (RBD) and spike, and observed that more positive B cells were induced upon the Alum + Poly(I:C) combination. Moreover, these B cells produced antibodies against both RBD and non-RBD sites. We also studied the impact of this vaccination preparation (spike protein with Alum + Poly(I:C)) in the lungs of mice challenged with inactivated SARS-CoV-2 virus. We found a production of IgG, but not IgA, and a reduction in neutrophil recruitment in the bronchoalveolar lavage fluid (BALF) of mice, suggesting that our immunization scheme reduced lung inflammation. Altogether, our data suggest that Alum and Poly(I:C) together is a possible adjuvant combination for vaccines against SARS-CoV-2 by the intradermal route.

Intradermal (ID) vaccination has been shown to be a promising strategy to increase the immune response against pandemic viruses such as H5N1 (1), Ebola (2), Vaccinia (3) , and SARS-CoV-2 (4) . This strategy has already been tested for vaccines against other betacoronaviruses such as SARS-CoV (5, 6) , and MERS-CoV (7) . Furthermore, the ID route has also been used for clinical trials of MERS-CoV (NCT03721718) and SARS-CoV-2 vaccines (4, 8) .

Currently, there are many mRNA and DNA vaccine candidates administered ID against SARS-CoV-2 in mice (9, 10) , non-human primates (11) and rabbits (12) . Covaxin, an inactivated vaccine developed by Indian pharmaceutical company, Bharat Biotech, was previously tested in mice, rats, and rabbits by the ID route, although the study had focused on the intramuscular (IM) route (13) . Now, Bharat Biotech is focusing their studies in applying their vaccine by the ID route, demonstrating the great potential of this route.

The advantages of the ID route include its easy administration through the use of painless microneedles that penetrate the skin, thus increasing vaccination acceptance and coverage, in addition to reducing errors in application and ensuring greater stability of the vaccine formulation (14) . Besides, ID immunization has shown success to expand the germinal center (GC) (15) , where plasma and memory B cells are regularly generated (16, 17) . Potent elicitation of GC response has been demonstrated in experimental mice model of vaccination, which in its turn was highly related to the induction of specific antibodies against SARS-CoV-2, as well as neutralizing antibodies (10, 18, 19) .

Furthermore, ID has already been shown to be a convenient route for the delivery of adjuvants (1) . Polyinosinic:polycytidylic acid (Poly(I:C)) is a synthetic analogue of double-stranded (ds) RNA, a molecular pattern associated with viral infections (20) . Poly(I:C) triggers a potent type 1 interferon (IFN) response through Toll-like receptor 3 (TLR3) and RIG-I-like receptor (RLR) (21) . The activation of these receptors can induce expression of cytokines, chemokines, costimulatory factors, and other dsRNA-dependent systems, resulting in a cellular immune response for viral clearance (20) .

A study comparing the role of Poly(I:C) and two derivatives as adjuvants in rhesus macaques demonstrated that treatment with all three Polys were able to induce T cell proliferation (22) . Ampligen has been shown to enhance the immunogenicity of an H1N1 influenza vaccine in mice (23) . PIKA, a stabilized derivative of Poly(I:C), was reported to be an adequate adjuvant candidate for an inactivated SARS-CoV vaccine, inducing strong anti-SARS-CoV mucosal and systemic humoral immune responses like IgA and IgG (24) . Sun et al 25 reported that Ad5-hACE2-transduced mice, when treated intranasally with Poly(I:C), triggered weight loss control and led to greater viral clearance. Furthermore, Zhao, Wang and Wu showed that HLA-A*0201/Kb transgenic (Tg) mice injected subcutaneously (SC) with Poly(I:C) were able to induce a slight enhancement of SARS-CoV spike peptide-specific CD8 + T cells 26 , demonstrating the potential use of Poly(I:C) as a vaccine candidate against SARS-CoV-2.

It was demonstrated that an inactivated vaccine candidate against MERS-CoV using Alum and MF59 adjuvants was able to induce neutralizing antibodies and reduce the viral load in the lungs of experimentally infected mice (22) . On the other hand, increased lung immunopathology was observed which was associated with intense cell infiltration of eosinophils (27) . However, to reduce eosinophilic infiltration in the lungs of mice, Iwata-Yoshikawa et al 28 Data presented so far suggest that a vaccine given by the ID route using Poly(I:C) and Alum adjuvants could have great potential for a vaccination strategy against SARS-CoV-2. Here, we assess a vaccination strategy using SARS-CoV-2 spike protein in combination with Alum and Poly(I:C) adjuvants by an intradermal (ID) route in a mouse model. After one or two boosts, we found high levels of IgG, IgG1 and IgG2a anti-spike serum antibodies, high neutralizing titers against SARS-CoV-2 and more Spike + RBD + B cells in germinal center induced upon the Alum + Poly(I:C) combination. We also found the production of IgG, but not IgA, and a reduction in neutrophil recruitment in the BALF of mice in the challenge with inactivated SARS-CoV-2. Altogether, our data suggest that Alum and Poly(I:C) together is a great strategy for use in combination as adjuvants for vaccines against SARS-CoV-2.

Female BALB/c mice, 6-8 weeks old (n = 5 per group), were obtained from the breeding facility of UFRJ. All animals were kept in mini-isolators (Alesco, São 

The immunogen used is the whole soluble ectodomain (aminoacids 1-1208) of the spike (S) protein of SARS-CoV-2, containing mutations that stabilize it as a trimer in the prefusion conformation, as first proposed by Wrapp et al 30 . The recombinant HEK293-derived affinity-purified S protein was obtained from the Cell Culture Engineering Laboratory of COPPE/UFRJ, and its purity and antigenicity have already been confirmed in previous works that used it to develop serological tests (31) and equine hyperimmune F(ab')2 preparations (32). This protein was used in this work to immunize mice and as ELISA antigen to detect anti-SARS-CoV-2 antibodies in samples from immunized animals. Moreover, it was also labeled with Alexa-fluor-467 (similar to APC) and used in germinal center experiments.

RBD (receptor-binding domain): cloning: synthetic gene S1-seq263-685 CoVID-2019_HKU-SZ-005b_2020 (MN975262) (length: 1302 bp) cloned into pET21a(+) using cloning sites NdeI and SalI purchased from Genscript Inc. (USA).

Chemically competent E. coli BL21(λDE3) (Novagen, USA) were transformed with 0.2 ng of the pET21a-plasmid, and positive clones were selected in an LBagar medium containing 100 μg/mL ampicillin at 37 ˚C overnight. A single positive colony was inoculated in 10 mL of LB medium containing 100 μg/mL ampicillin and this culture was stirred at 220 rpm at 37 ˚C overnight.

The overnight culture was diluted to 1:100 in 2 L of fresh medium (with antibiotic) and grown at 37 °C until an optical density (O.D.600nm) between 0.6 to 0.8, when the protein expression was induced with 1 mM IPTG followed by 6 h of expression at 37 °C with 220 rpm stirring. Then, the cells were harvested by centrifugation at 5000 × g for 15 min at 4 °C, and the total-cell lysate was prepared (33) .

The pellet was resuspended in 5 mL of buffer A (50 mM sodium phosphate, 200 mM sodium chloride, 1 mM ß-mercaptoethanol, 5 % glycerol, pH 7.0) per gram of pellet, with 1 mM PMSF. Then added 5 mg/mL of lysozyme and stirring for 30 min at 4 °C. After this, 10 µg/mL of DNase A, and 2 mM of MgCl2 were added, and the solution was incubated for 30 min at 4 °C. The total-cell lysate was sonicated using 15 cycles of 15 s on and 45 s off at 300 W (34) . The purification of inclusion bodies was performed by centrifugation at 27,000 × g for 60 min at 4 °C. Finally, the inclusion bodies were resuspended in buffer B (50 mM sodium phosphate, 200 mM sodium chloride, 1 mM ß-mercaptoethanol, 5% glycerol, 8 M urea, 10 mM imidazole, pH 7.0) overnight at 4 °C 1 . The pellet was resuspended overnight under strong stirring. Next day, the solution was centrifuged at 32,000

x g for 1 h and sequentially filtered through 1, 0.45 and 0.22 µm filters.

The purification of RBD protein was carried out by affinity chromatography. The protein solubilized in the previous step were subjected to a Ni HP-5 column (5 mL, GE Healthcare, USA), previously equilibrated with 5 CV of Buffer C (buffer C (50 mM sodium phosphate pH 7.0, 0.01 M imidazole and 8 M urea). The nonspecific ligands were removed by washing the column with 5 CV of Buffer C.

The elution was performed using a gradient of Buffer C and Buffer D (buffer D, 50 mM sodium phosphate pH 7.0, 0.5 M imidazole and 8 M urea) at a flow rate of 2 mL/min (35) . All collected samples were analyzed by SDS-PAGE (36) , and the tubes containing the purified interesting protein were pooled and dialyzed in storage buffer.

To start labeling proteins with the Alexa kits from ThermoFisher, initially a dialysis was performed to transfer all proteins to PBS buffer. This procedure is recommended by the company to obtain results with a greater labeling efficiency.

After this step, the proteins were quantified by Bradford method and then the standard protocol was continued (37) . Then, 100 g of protein S and RBD were labeled with kits Alex-fluor-488 (494/519) and Alex-fluor-647 (650/688).

African green monkey kidney cells (Vero, subtype E6) were cultured in high freezers.

The SARS-CoV particles were inactivated with β-propiolactone for 24 hours, followed by concentration in 30 % sucrose cushion in 30000 RPM for 1:30 hour.

The, the pellet was resuspended in phosphate buffer sodium and storege at -

Mice were anesthetized using an induction chamber with an atmosphere 

Mice were immunized three times by intranasal route by installation of 5 µg of Spike protein alone associated with 5 µg Poly (I:C) as adjuvant. (25) .

To assess the neutralization titer, the serum samples were incubated with 100 

Results are expressed as mean ± SEM with confidence level of p ≤ 0.05. For multiple comparisons, a one-way ANOVA followed by Tukey multiple comparison test was performed. Paired t-test analysis was done where indicated in the figure legends. Data analysis was performed using GraphPad Prism® 8.0 software. Figures 1B and 1C , respectively).

In order to check whether the lack of a specific antibody response in the BALF was due to the immunization route, we performed an intranasal immunization. This route appeared to efficiently increase the amount of IgA (Supplementary Figure 1D) and IgG (Supplementary Figure 1E ) in the groups vaccinated with S Ptn + Poly(I:C) in comparison to S Ptn.

The presence of IgG1 is usually related to a type 2 immune response while

IgG2a is related to a type 1 response. To understand which response was being induced by the immunizations, we evaluated these IgG subtype (IgG1 and IgG2a) levels in the serum. We found that mice immunized with S Ptn + Poly(I:C), S Ptn Figures 3G and 3H) . Furthermore, mice immunized with S Ptn + Alum had a higher level of O.D. Sum than the S Ptn group after one boost ( Figure 3F ).

Together, these data suggest that all adjuvant-containing formulations induce IgG in the serum, but the ones containing Poly(I:C) are able to induce a strong type 1 antibody response against SARS-CoV-2 spike protein, while the ones containing Alum were able to induce slightly higher IgG levels in the BALF ( Figure 1E ). Immunization with S Ptn alone generated more type 2 antibodies in the serum than the groups containing adjuvants.

We assessed the in vitro neutralizing activity against SARS-CoV-2 in mouse sera collected one week after two and three immunizations (days 21 after first immunization) ( Figure 4 ). We did not observe neutralizing antibodies in the sera of mice immunized with S Ptn, as measured by the neutralizing titers of Figures   5D and 5E ). In this cell population, there was an increase in the frequency of RBD + S Ptn + cells in the group that received S Ptn + Alum, when compared to the group that received S Ptn + Poly(I:C) and the control groups ( Figure 5F ).

However, we saw that there was a greater number of these cells in the group that received S Ptn + Poly(I:C) + Alum, when compared either to the control groups, the group that received only S Ptn, and the group that received S Ptn + Poly(I:C) ( Figure 5G ). We also evaluated cells that were RBD -S Ptn + and did not observe differences between the groups (Figures 5H and 5I) .

We also continued with the analysis of cells outside the germinal center and noticed that there was a reduction in the frequency of CD38 + GL7cells in the group that received S Ptn + Poly(I:C) + Alum in relation to the other groups ( Figure   6A ). The same was not observed for the number of cells though ( Figure 6B ). In this cell population, we also observed that the S Ptn + Alum group had an increase in the percentage and number of RBD + S Ptn + cells when compared to the other groups ( Figures 6C and 6D ). Figure 7F ).

The ID route has recently been shown to be an optimal immunization strategy against SARS-CoV-2 due to its ability to stimulate Antigen Presenting Cells (APCs), such as Dendritic cells (DCs) and macrophages, in the dermis, which presents high vascularization, facilitating the migration of cells to secondary lymphoid organs for T and B cell activation (42) . One of the main advantages of the ID route is that, due to the presence of a large number of APCs, it allows the administration of a lower dose of antigens and adjuvants is required to generate immune responses, unlike those necessary for the IM and SC routes (43) (44) (45) .

To this day, there have been two vaccines approved for use in humans against SARS-CoV-2, PiCoVacc (46) and BBIBP-CorV (47) , that use the adjuvant Alum in the formulation together with purified virus inactivated by β-propiolactone.

Zhang et al 46 

The animal study was reviewed and approved by the Animal Ethical Committee 

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. groups; * -represents differences between S Ptn and S Ptn + Poly(I:C) groups;

+ -represents differences between S Ptn and S Ptn + Alum groups; § -represents differences between S Ptn and S Ptn + Poly(I:C) + Alum groups; $ -represents differences between S Ptn + Poly(I:C) and S Ptn + Poly(I:C) + Alum groups; & -represents differences between S Ptn + Poly(I:C) and S Ptn + Alum groups; 'represents differences between S Ptn + Alum and S Ptn + Poly(I:C) + Alum groups; ♪ -represents differences between Naïve and S Ptn groups. 

The adjuvant GLA-AF enhances human intradermal vaccine responses

Intradermal Syncon® Ebola GP DNA Vaccine Is Temperature Stable And Safely Demonstrates Cellular And Humoral Immunogenicity Advantages In Healthy Volunteers

Comparison Of Lyophilized Versus Liquid Modified Vaccinia Ankara (MVA) Formulations And Subcutaneous Versus Intradermal Routes Of Administration In Healthy Vaccinia-Naïve Subjects

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label

Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments

Optimization of a DNA vaccine against SARS

Spike Protein Vaccine and Inactivated Influenza Vaccine Formulated with Single Strand RNA Adjuvant Induce T-Cell Activation through Intranasal Immunization in Mice

Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India

Immunogenicity of a DNA vaccine candidate for COVID-19

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2

Intradermal-delivered DNA vaccine provides anamnestic protection in a rhesus macaque SARS-CoV-2 challenge model

SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus

Evaluation of Safety and Immunogenicity of an Adjuvanted, TH-1 Skewed, Whole Virion InactivatedSARS-CoV-2 Vaccine -BBV152

Transdermal delivery of vaccines -Recent progress and critical issues

Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses

Germinal-Center Organization and Cellular Dynamics

SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Vaccine adjuvant uses of poly-IC and derivatives

dsRNA-Activation of TLR3 and RLR Signaling: gene Induction-Dependent and Independent Effects

Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques

PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants

PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV

Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment

The immune responses of HLA-A*0201 restricted SARS-CoV S peptide-specific CD8 + T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848

Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus

Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine

Novel chimeric virus-like particles vaccine displaying MERS-CoV receptorbinding domain induce specific humoral and cellular immune response in mice

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Potent neutralizing equine antibodies raised against recombinant SARS-CoV-2 spike protein for COVID-19 passive immunization therapy

Molecular cloning : a laboratory manual

Purification of proteins by IMAC

Tricine-SDS-PAGE

A neutrophil activation signature predicts critical illness and mortality in COVID-19

Neutrophil-to-lymphocyte ratio and lymphocyte-to-Creactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. (2020)

COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Vaccination into the dermal compartment: techniques, challenges, and prospects. Vaccines (Basel)

Intradermal Delivery of Vaccines: A Review of the Literature and the Potential for Development for Use in Low-And Middle-Income Countries

Intradermal Vaccination: A Potential Tool in the Battle Against the COVID-19 Pandemic

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

Formulation of aluminum hydroxide adjuvant with TLR agonists poly(I:C) and CpG enhances the magnitude and avidity of the humoral immune response

Poly(I:C)/Alum Mixed Adjuvant Priming Enhances HBV Subunit Vaccine-Induced Immunity in Mice When Combined with Recombinant Adenoviral-Based HBV Vaccine Boosting

Prophylactic and therapeutic intranasal administration with an immunomodulator, Hiltonol ® (Poly IC:LC), in a lethal SARS-CoV-infected BALB/c mouse model

Landscape and selection of vaccine epitopes in SARS-CoV-2

Alum:CpG adjuvant enables SARS-CoV-2 RBD-induced protection in aged mice and synergistic activation of human elder type 1 immunity

Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals. medRxiv

Baricitinib treatment resolves lower-airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques

We thank Professor Leda Castilho from COPPE/UFRJ to donate Spike protein for this study. We also thank Serrapilheira, FAPERJ and CNPq for financial support.